Bispecific Antibody Myeloma Study

Join the Study Today

Study Question

What are real-world patient experiences with the use of bispecific antibodies as a treatment for multiple myeloma?

Description

The multiple myeloma medical community is now able to provide bispecific antibody therapy to patients. This is a major study initiative that will be open to patients receiving bispecific antibodies, and will be open for enrollment for a minimum of 3 years. The study consists of 8 surveys designed to gather information about various aspects of the patient experience with bispecific antibodies, ranging from initial awareness to quality of life after at least four months of treatment. The surveys cover topics such as treatment decision-making, side effects, outcomes, caregiver involvement, financial aspects, and quality of life.

Because there are now three FDA approved bispecific antibodies with more coming in clinical development, this is critical information doctors need to know to correctly prescribe this therapy to myeloma patients.

Impact

This 3-year study will identify patient experiences in the treatment process, patient experiences with step-up dosing, patient experiences in academic center vs. general oncology centers, the caregiver burden, side effects experienced and patient outcomes. This extensive study will help identify the type of patient best helped by this class of treatment and the optimal sequencing of bispecific antibodies in myeloma care.

Type

This study includes 8 surveys and medical records connections

Time

Each survey will take 10-25 minutes. The medical records connection takes less than 5 minutes.

Research Partners

Who Can Join

Multiple myeloma patients after at least 4 months of having received a bispecific antibody (as an FDA-approved treatment or as part of a clinical trial).